133 219

Cited 0 times in

Stage 3 플러스 징후를 동반한 미숙아 망막병증에서 일차유리체강내 베바시주맙 주입술의 효과

DC FieldValueLanguage
dc.contributor.author이승규-
dc.contributor.author임형택-
dc.contributor.author김성은-
dc.date.accessioned2016-02-04T11:25:46Z-
dc.date.available2016-02-04T11:25:46Z-
dc.date.issued2015-
dc.identifier.issn0378-6471-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140404-
dc.description.abstractPurpose: To evaluate the efficacy and safety of primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs. Methods: We reviewed retrospectively the medical records of 30 eyes of 16 patients diagnosed with stage 3 retinopathy of prematurity with plus signs treated with primary intravitreal bevacizumab injection between March 1, 2011 and February 28, 2013 and followed up for at least 9 months. Results: Mean gestational age was 26 + 4 weeks ± 11 days and mean birth weight was 822 ± 251.4 g. The locations of disease were zone II in 24 eyes and zone III in 6 eyes. Intravitreal bevacizumab injection was performed after the mean 1.3 ± 1 day after plus signs were detected. Mean postconceptional age at treatment was 38 + 2 weeks ± 16 days. Mean follow-up period was 16.6 ± 6.9 months. Plus signs started to regress after the mean 4.6 ± 2.3 days after injection and completely regressed after the mean 24.3 ± 12.4 days. Cataract extraction was performed in 1 eye due to a cataract that appeared not associated with the injection procedure, but was regarded as a treatment failure. There were no local or systemic complications. Conclusions: Primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs demonstrated excellent short-term efficacy and safety.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.relation.isPartOfJOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleStage 3 플러스 징후를 동반한 미숙아 망막병증에서 일차유리체강내 베바시주맙 주입술의 효과-
dc.title.alternativeEffect of Primary Intravitreal Bevacizumab Injection on Stage 3 Retinopathy of Prematurity with Plus Signs-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학)-
dc.contributor.googleauthor김성은-
dc.contributor.googleauthor임형택-
dc.contributor.googleauthor이승규-
dc.identifier.doi10.3341/jkos.2015.56.1.62-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02913-
dc.contributor.localIdA03419-
dc.relation.journalcodeJ01838-
dc.identifier.eissn2092-9374-
dc.subject.keywordAvastin-
dc.subject.keywordBevacizumab-
dc.subject.keywordRetinopathy of prematurity-
dc.contributor.alternativeNameLee, Seung Kyu-
dc.contributor.alternativeNameRim, Tyler H. T.-
dc.contributor.affiliatedAuthorLee, Seung Kyu-
dc.contributor.affiliatedAuthorRim, Tyler Hyungtaek-
dc.rights.accessRightsfree-
dc.citation.volume56-
dc.citation.number1-
dc.citation.startPage62-
dc.citation.endPage69-
dc.identifier.bibliographicCitationJOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, Vol.56(1) : 62-69, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.